← All stocks

Passage BIO, Inc.

PASG Net buying
CIK 0001787297 #5149 in the set updated 18 Sep 2026
Bought (120 mo)
$43.03M
out of their own pocket, the only kind of buying there is
Sold (120 mo)
$1.94M
$0.00 on a plan · $341.38K straight out of an exercise
Sold at will
$1.60M
36 of 43 sales
Net
+$41.09M
+$41.43M against sales at will

By person

22 insiders · 86 transactions
Insider
Role
Bought
Sold
Net
Holding
Worth
Change
ORBIMED ADVISORS LLC entity
10% owner
$12.48M (12)
$1.01M (25)
+$11.47M
20,047,666
$82.55M
+46.7%
Frazier Life Sciences IX, L.P.
10% owner
$9.90M (1)
+$9.90M
5,009,219
$20.63M
Heron Patrick J
Director
$9.90M (1)
+$9.90M
5,009,219
$20.63M
Versant Venture Capital VI, L.P. entity
10% owner
$4.05M (1)
+$4.05M
4,959,769
$20.42M
Woiwode Thomas
Director
$4.05M (1)
+$4.05M
4,959,769
$20.42M
Lynx1 Capital Management LP entity
10% owner
$1.69M (11)
+$1.69M
673,759
$2.77M
Quigley Jill M.
Chief Operating Officer
$45.00K (2)
$529.58K (2)
−$484.58K
369,754
$1.52M
+31.9%
Countouriotis Athena
Director
$309.95K (2)
+$309.95K
18,900
$77.82K
Romano Gary
Chief Medical Officer
$211.01K (2) scheduled
−$211.01K
0
$0.00
Yamada Tadataka
Director
$117.00K (1)
+$117.00K
656,149
$2.70M
+1.0%
Fotopoulos Alexandros
Chief Technical Officer
$99.00K (1)
$8.73K (2) scheduled
+$90.27K
28,693
$118.14K
+381.0%
Islam Saqib
Director
$90.00K (1)
+$90.00K
5,000
$20.59K
Kapadia Sandip
Director
$90.00K (1)
$5.96K (1)
+$84.04K
0
$0.00
Goldsmith Bruce A
CEO and President
$77.53K (3)
+$77.53K
15,983
$65.81K
+454.4%
Chou William
PRESIDENT AND CEO
$75.16K (1) scheduled
−$75.16K
6,524
$26.86K
+987.3%
Borthwick Kathleen
CFO
$50.85K (4) scheduled
−$50.85K
5,402
$22.24K
Ratcliffe Liam
Director
$50.40K (1)
+$50.40K
2,800
$11.53K
Morris Richard Steven
Chief Financial Officer
$37.20K (2)
+$37.20K
5,454
$22.46K
+89.2%
Cale Edgar B.
GC & CORPORATE SECRETARY
$36.00K (1)
$14.39K (1)
+$21.61K
45,995
$189.38K
+369.0%
Forman Mark S
CHIEF MEDICAL OFFICER
$15.98K (2)
−$15.98K
48,631
$200.24K
+338.8%
King Simona
Chief Financial Officer
$12.23K (2) scheduled
−$12.23K
23,994
$98.80K
Toernsen Monika Maria
Chief Commercial Officer
$2.54K (1)
−$2.54K
3,319
$13.67K

No percentages here. This company's share count has moved by a factor of 19.6 over the window, from 3,178,710 to 62,148,274 shares. A split, a merger or a large issue changes what the company is, and a holding measured at one point in that run is not a fraction of it at another.

Insider
Date
Role
Action
Shares
Price
Amount
Lynx1 Capital Management LP
25 Jun 2026
10% owner
Buy indirect
50,055
$4.12
$206.10K
Lynx1 Capital Management LP
15 Sep 2025
10% owner
Buy indirect
11,900
$6.99
$83.18K
Lynx1 Capital Management LP
12 Sep 2025
10% owner
Buy indirect
19,783
$6.99
$138.30K
Lynx1 Capital Management LP
11 Sep 2025
10% owner
Buy indirect
325
$6.96
$2.26K
Lynx1 Capital Management LP
24 Jul 2025
10% owner
Buy indirect
66,423
$5.71
$379.45K
Lynx1 Capital Management LP
23 Jul 2025
10% owner
Buy indirect
49,302
$5.74
$283.03K
Lynx1 Capital Management LP
22 Jul 2025
10% owner
Buy indirect
13,123
$5.44
$71.34K
Lynx1 Capital Management LP
27 Dec 2024
10% owner
Buy indirect
373,645
$0.65
$241.04K
Lynx1 Capital Management LP
27 Nov 2024
10% owner
Buy indirect
29,300
$0.67
$19.66K
Lynx1 Capital Management LP
26 Nov 2024
10% owner
Buy indirect
167,055
$0.71
$118.19K
Lynx1 Capital Management LP
25 Nov 2024
10% owner
Buy indirect
259,998
$0.56
$146.66K
ORBIMED ADVISORS LLC
28 Jun 2023
10% owner
Buy indirect
575,195
$0.84
$483.16K
ORBIMED ADVISORS LLC
27 Jun 2023
10% owner
Buy indirect
617,382
$0.84
$518.60K
ORBIMED ADVISORS LLC
4 May 2022
10% owner
Buy indirect
303,500
$1.94
$588.79K
ORBIMED ADVISORS LLC
3 May 2022
10% owner
Buy indirect
221,500
$1.93
$427.50K
Goldsmith Bruce A
21 Mar 2022
CEO and President
Buy
10,000
$3.15
$31.50K
ORBIMED ADVISORS LLC
20 Jan 2022
10% owner
Buy indirect
369,100
$5.42
$2.00M
ORBIMED ADVISORS LLC
19 Jan 2022
10% owner
Buy indirect
43,300
$5.11
$221.26K
ORBIMED ADVISORS LLC
18 Jan 2022
10% owner
Buy indirect
114,700
$5.46
$626.26K
ORBIMED ADVISORS LLC
14 Jan 2022
10% owner
Buy indirect
10,300
$5.60
$57.68K
ORBIMED ADVISORS LLC
13 Jan 2022
10% owner
Buy indirect
41,800
$5.52
$230.74K
ORBIMED ADVISORS LLC
12 Jan 2022
10% owner
Buy indirect
100,000
$5.65
$565.00K
ORBIMED ADVISORS LLC
11 Jan 2022
10% owner
Buy indirect
8,200
$5.53
$45.35K
Goldsmith Bruce A
21 May 2021
CEO and President
Buy
2,000
$13.12
$26.23K
Morris Richard Steven
21 May 2021
Chief Financial Officer
Buy
2,171
$13.82
$30.00K
Countouriotis Athena
24 Mar 2020
Director
Buy
10,000
$14.98
$149.75K
Cale Edgar B.
3 Mar 2020
GC and Corporate Secretary
Buy
2,000
$18.00
$36.00K
Countouriotis Athena
3 Mar 2020
Director
Buy
8,900
$18.00
$160.20K
Fotopoulos Alexandros
3 Mar 2020
Chief Technical Officer
Buy
5,500
$18.00
$99.00K
Goldsmith Bruce A
3 Mar 2020
CEO and President
Buy
1,100
$18.00
$19.80K
Islam Saqib
3 Mar 2020
Director
Buy
5,000
$18.00
$90.00K
Kapadia Sandip
3 Mar 2020
Director
Buy
5,000
$18.00
$90.00K
Morris Richard Steven
3 Mar 2020
Chief Financial Officer
Buy
400
$18.00
$7.20K
Quigley Jill M.
3 Mar 2020
Chief Operating Officer
Buy indirect
1,000
$18.00
$18.00K
Quigley Jill M.
3 Mar 2020
Chief Operating Officer
Buy
1,500
$18.00
$27.00K
Ratcliffe Liam
3 Mar 2020
Director
Buy
2,800
$18.00
$50.40K
Yamada Tadataka
3 Mar 2020
Director
Buy
6,500
$18.00
$117.00K
Heron Patrick J
3 Mar 2020
Director
Buy indirect
550,000
$18.00
$9.90M
Woiwode Thomas
3 Mar 2020
Director
Buy indirect
225,000
$18.00
$4.05M
Frazier Life Sciences IX, L.P.
3 Mar 2020
10% owner
Buy
550,000
$18.00
$9.90M
Versant Venture Capital VI, L.P.
3 Mar 2020
10% owner
Buy indirect
225,000
$18.00
$4.05M
ORBIMED ADVISORS LLC
28 Feb 2020
10% owner
Buy indirect
373,300
$18.00
$6.72M

What was left out

Form 4 filings counted 163
Amendments (4/A) skipped 2
Filings about a different issuer 0
Unreadable filings 0
Joint filings 23
Sales on a Rule 10b5-1 plan 0
Sales straight out of an exercise 7
Sales at will 36
Transactions with no price 0
Shares from compensation/vesting 24,273,474
Sales filed before the plan box existed 4
History held since 2 Mar 2020